Evidence map›Paper›PMID 39827421›Full record

ArticleJournal of neuro-oncology2025

Prognostic and clinical significance of contrast enhancement in WHO grade 2 oligodendrogliomas.

Xuzhe Zhao, Yutao Zhang, Yonggang Wang, Xiaohui Ren, Xiaokang Zhang, Haibin Wan, Ming Li, Dabiao Zhou

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xuzhe ZhaoDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No.119 South Fourth Ring West Road, Fengtai District, Beijing, 100070, China.
Yutao ZhangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No.119 South Fourth Ring West Road, Fengtai District, Beijing, 100070, China.
Yonggang WangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No.119 South Fourth Ring West Road, Fengtai District, Beijing, 100070, China.
Xiaohui RenDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No.119 South Fourth Ring West Road, Fengtai District, Beijing, 100070, China.
Xiaokang ZhangDepartment of Neurosurgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Haibin WanDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No.119 South Fourth Ring West Road, Fengtai District, Beijing, 100070, China.
Ming LiDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No.119 South Fourth Ring West Road, Fengtai District, Beijing, 100070, China.
Dabiao ZhouDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No.119 South Fourth Ring West Road, Fengtai District, Beijing, 100070, China. dabiaozhou@163.com.ORCID http://orcid.org/0000-0002-2683-2580

Funding

Beijing Natural Science Foundation L246018National Natural Science Foundation of China 82151310
6 · The paper itself

Abstract

purposeTo investigate the prognostic significance of contrast enhancement (CE) in grade 2 oligodendroglioma (ODG) and explore its clinical implications.

methodsPatients diagnosed with isocitrate dehydrogenase (IDH)-mutant, 1p/19q co-deleted ODG between 2009 and 2016 were retrospectively enrolled from a single institution. The presence of CE was identified on preoperative MRIs, and clinical, radiologic, and histopathological data that was extracted. Subgroup analyses were performed to evaluate differences in these factors and prognoses. Cox proportional hazards regression analyses were used to identify prognostic factors.

results258 patients with pathologically confirmed WHO grade 2 ODGs were included. The entire cohort was divided into the CE group (n = 133, 51.6%) and the non-CE group (n = 125, 48.4%). Patients with CE on preoperative MRI showed significantly worse progression-free survival (PFS) compared to those without CE (median PFS: 133 months vs. not reached; p < 0.001) and overall survival (OS) (mean OS: 151 months vs. 155 months; median OS: not reached; p = 0.021). Furthermore, CE presence was identified as an independent prognostic factor in the Cox multivariate analysis. Patients within the CE cohort were further categorized into strong and weak CE subgroups based on the pattern of CE. Logistic regression analysis revealed that non-frontal lobe location (OR = 3.287, p = 0.042), higher Ki-67 index (OR = 3.782, p = 0.027), and 1q/19p co-polysomy (OR = 9.658, p = 0.001) were significantly associated with a higher incidence of the strong CE in ODGs. Furthermore, ODG patients in the strong CE subgroup demonstrated the poorest survival outcomes.

conclusionCE on preoperative MRI is a valuable prognostic marker in the grade 2 ODGs, with strong CE indicating the poorest survival outcomes. Further validation through larger cohort studies will help confirm these findings and refine survival stratification in clinical practice.

Indexed as

Brain NeoplasmsContrast MediaMagnetic Resonance ImagingOligodendrogliomaAdolescentAdultAgedClinical RelevanceFemaleFollow-Up StudiesHumansIsocitrate DehydrogenaseMaleMiddle AgedNeoplasm GradingPrognosisContrast MediaIsocitrate DehydrogenaseContrast enhancementGadoliniumNeuroimagingOligodendrogliomaPrognosis

Identifiers

PMID39827421

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.